- Home
- NPCE vs SIGA Comparison
NPCE vs SIGA Comparison
Compare NPCE & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NPCE | SIGA |
|---|---|---|
| Founded | 1997 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.3M | 486.2M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NPCE | SIGA |
|---|---|---|
| Price | $14.75 | $6.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.33 | N/A |
| AVG Volume (30 Days) | 143.6K | ★ 320.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.88% |
| EPS Growth | ★ 26.77 | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | ★ $79,906,000.00 | N/A |
| Revenue This Year | $25.95 | N/A |
| Revenue Next Year | $0.28 | $132.36 |
| P/E Ratio | ★ N/A | $16.90 |
| Revenue Growth | ★ 22.14 | N/A |
| 52 Week Low | $7.56 | $4.95 |
| 52 Week High | $18.97 | $9.62 |
Technical Indicators
Market Signals| Indicator | NPCE | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 53.53 |
| Support Level | $14.02 | $6.47 |
| Resistance Level | $16.96 | $7.00 |
| Average True Range (ATR) | 0.71 | 0.23 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 25.05 | 55.45 |
Price Performance
Historical ComparisonAbout NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.